LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.99 USD -9.17% Market Closed
Market Cap: 26m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
EPS (Diluted)
-$1
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
7%
ProQR Therapeutics NV
NASDAQ:PRQR
EPS (Diluted)
€0
CAGR 3-Years
29%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
EPS (Diluted)
-$4
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
-7%
argenx SE
XBRU:ARGX
EPS (Diluted)
-$4
CAGR 3-Years
24%
CAGR 5-Years
-12%
CAGR 10-Years
-31%
Merus NV
NASDAQ:MRUS
EPS (Diluted)
-$3
CAGR 3-Years
-20%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
26m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.18 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's EPS (Diluted)?
EPS (Diluted)
-1.6 USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's EPS (Diluted) amounts to -1.6 USD.

What is LAVA Therapeutics NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-37%

Over the last year, the EPS (Diluted) growth was -28%. The average annual EPS (Diluted) growth rates for LAVA Therapeutics NV have been -37% over the past three years .

Back to Top